Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/ajg.2013.222 http://scihub22266oqcxt.onion/10.1038/ajg.2013.222 C4046950!4046950!23857477     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Gastroenterol 2013 ; 108 (10): 1576-83 Nephropedia Template TP {{tp|p=23857477|t=2013. Oral Bisphosphonates and the Risk of Barrett s Esophagus: Case?Control Analysis of US Veterans |pdf=|usr=}}{{23857477}} gab.com Text Oral Bisphosphonates and the Risk of Barrett s Esophagus: Case Control Analysis of US Veterans JO: Am J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=23857477 #FOAvip OBJECTIVES: This study examined Barrett's esophagus (BE) risk factors in veterans to determine the association between risk of BE and use of oral bisphosphonates. METHODS: We conducted a case ? control study among eligible patients scheduled for an elective esophagogastroduodenoscopy (EGD) and a sample of patients eligible for screening colonoscopy recruited from primary care clinics from a single VA Medical Center. Cases with definitive BE were compared with controls; all underwent study EGD. Use of oral bisphosphonates was ascertained by reviewing filled prescriptions in electronic pharmacy records. We calculated odds ratios (ORs) and 95% confidence intervals (95% CIs), using multivariate logistic regression modeling while adjusting for sex, age, race, proton-pump inhibitor use, hiatal hernia, waist-to-hip ratio, Helicobacter pylori infection, and gastroesophageal reflux disorder (GERD) symptoms. RESULTS: There were 285 BE cases, 1,122 endoscopy controls, and 496 primary care controls. Alendronate and risedronate were the only oral bisphosphonates prescribed. The proportion of BE cases with filled prescription of oral bisphosphonates (4.6%) was greater than in endoscopy controls (1.6%) or primary care controls (2.9%). In the adjusted analysis, oral bisphosphonate use was significantly associated with BE risk (OR = 2.33; 95% CI: 1.11 ? 4.88) compared with the combined control groups. This association remained significant when BE cases were compared with endoscopy controls only (OR = 2.74; 95% CI: 1.28 ? 5.87) but was attenuated when compared with primary care controls only (OR = 2.60; 95% CI: 0.99 ? 6.84). The association was observed in patients with GERD symptoms (OR = 3.29; 95% CI: 1.36 ? 7.97) but not in those without GERD symptoms. CONCLUSIONS: Oral bisphosphonate use may increase the risk for BE, especially among patients with GERD. Twit Text FOAVip Oral Bisphosphonates and the Risk of Barrett s Esophagus: Case Control Analysis of US Veterans ????Am J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=23857477 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23857477 #FOAvip English Wikipedia <ref>{{Cite pmid|23857477}}</ref> Oral Bisphosphonates and the Risk of Barrett s Esophagus: Case?Control Analysis of US Veterans #MMPMID23857477 Lin D; Kramer JR; Ramsey D; Alsarraj A; Verstovsek G; Rugge M; Parente P; Graham DY; El-Serag HB Am J Gastroenterol 2013[Oct]; 108 (10): 1576-83 PMID23857477show ga OBJECTIVES: This study examined Barrett's esophagus (BE) risk factors in veterans to determine the association between risk of BE and use of oral bisphosphonates. METHODS: We conducted a case ? control study among eligible patients scheduled for an elective esophagogastroduodenoscopy (EGD) and a sample of patients eligible for screening colonoscopy recruited from primary care clinics from a single VA Medical Center. Cases with definitive BE were compared with controls; all underwent study EGD. Use of oral bisphosphonates was ascertained by reviewing filled prescriptions in electronic pharmacy records. We calculated odds ratios (ORs) and 95% confidence intervals (95% CIs), using multivariate logistic regression modeling while adjusting for sex, age, race, proton-pump inhibitor use, hiatal hernia, waist-to-hip ratio, Helicobacter pylori infection, and gastroesophageal reflux disorder (GERD) symptoms. RESULTS: There were 285 BE cases, 1,122 endoscopy controls, and 496 primary care controls. Alendronate and risedronate were the only oral bisphosphonates prescribed. The proportion of BE cases with filled prescription of oral bisphosphonates (4.6%) was greater than in endoscopy controls (1.6%) or primary care controls (2.9%). In the adjusted analysis, oral bisphosphonate use was significantly associated with BE risk (OR = 2.33; 95% CI: 1.11 ? 4.88) compared with the combined control groups. This association remained significant when BE cases were compared with endoscopy controls only (OR = 2.74; 95% CI: 1.28 ? 5.87) but was attenuated when compared with primary care controls only (OR = 2.60; 95% CI: 0.99 ? 6.84). The association was observed in patients with GERD symptoms (OR = 3.29; 95% CI: 1.36 ? 7.97) but not in those without GERD symptoms. CONCLUSIONS: Oral bisphosphonate use may increase the risk for BE, especially among patients with GERD. äOral Bisphosphonates and the Risk of Barrett s Esophagus: Case?Control(epmc).pdf DeepDyve Pubget Overpricing